Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Institutional Ownership Changes (13F Filings) for Elicio Therapeutics (NASDAQ:ELTX)CurrentInstitutional OwnershipPercentage35.03%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$649.50KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$102.75K Get ELTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Elicio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELTX Institutional Buying and Selling by Quarter Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Elicio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024 Armistice Capital LLC100,000$411K0.0%N/A0.978% 8/9/2024 Warberg Asset Management LLC11,801$49K0.0%N/A0.115% 8/2/2024 CM Management LLC50,000$206K0.2%-33.3%0.489% 5/14/2024 CM Management LLC75,000$570K0.5%+50.0%0.733% 8/4/2023 CM Management LLC65,000$618K0.6%N/A2.159% (Data available from 1/1/2016 forward) ELTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELTX shares? During the previous two years, the following institutional investors and hedge funds held shares of Elicio Therapeutics shares: Armistice Capital LLC ($411K), and CM Management LLC ($206K), Warberg Asset Management LLC ($49K).Learn more on ELTX's institutional investors. What percentage of Elicio Therapeutics stock is owned by institutional investors? 35.03% of Elicio Therapeutics stock is owned by institutional investors. Learn more on ELTX's institutional investor holdings. Which institutional investors have been buying Elicio Therapeutics stock? The following institutional investors have purchased Elicio Therapeutics stock in the last 24 months: Armistice Capital LLC ($100K), CM Management LLC ($90K), and Warberg Asset Management LLC ($11.80K). How much institutional buying is happening at Elicio Therapeutics? Institutional investors have bought a total of 201,801 shares in the last 24 months. This purchase volume represents approximately $1.27M in transactions. Which Elicio Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Elicio Therapeutics stock in the last 24 months: CM Management LLC ($25K). How much institutional selling is happening at Elicio Therapeutics? Institutional investors have sold a total of 25,000 shares in the last 24 months. This volume of shares sold represents approximately $102.75K in transactions. Related Companies BMEA Institutional Ownership XBIT Institutional Ownership VSTM Institutional Ownership LFVN Institutional Ownership MGNX Institutional Ownership PRQR Institutional Ownership SLN Institutional Ownership CYBN Institutional Ownership PGEN Institutional Ownership LYEL Institutional Ownership This page (NASDAQ:ELTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts